The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer
Open accessAbstract
BACKGROUND & AIMS: We aimed to investigate the clinical utility of circulating tumor cell DNA (ctDNA) and exosome DNA (exoDNA) in pancreatic cancer. METHODS: We collected liquid biopsy samples from 194 patients undergoing treatment for localized or metastatic pancreatic adenocarcinoma from April 7, 2015, through October 13, 2017 (425 blood samples collected before [baseline] and during therapy). Additional liquid biopsy samples were collected from 37 disease control individuals. Droplet digital polymerase chain reaction was used to determine KRAS mutant allele fraction (MAF) from ctDNA and exoDNA purified from plasma. For the longitudinal analysis, we analyzed exoDNA and ctDNA in 123 serial blood samples from 34 patients. We performed analysis including Cox regression, Fisher exact test, and Bayesian inference to associate KRAS MAFs in exoDNA and ctDNA with prognostic and predictive outcomes. RESULTS: In the 34 patients with potentially resectable tumors, an increase in exoDNA level after neoadjuvant therapy was significantly associated with disease progression (P = .003), whereas ctDNA did not show correlations with outcomes. Concordance rates of KRAS mutations present in surgically resected tissue and detected in liquid biopsy samples were greater than 95%. On univariate analysis, patients with metastases and detectable ctDNA at baseline status had significantly shorter times of progression-free survival (PFS) (hazard ratio [HR] for death, 1.8; 95% CI, 1.1–3.0; P = .019), and overall survival (OS) (HR, 2.8; 95% CI, 1.4–5.7; P = .0045) compared with patients without detectable ctDNA. On multivariate analysis, MAFs ≥5% in exoDNA were a significant predictor of PFS (HR, 2.28; 95% CI, 1.18–4.40; P = .014) and OS (HR, 3.46; 95% CI, 1.408.50; P = .007). A multianalyte approach showed detection of both ctDNA and exoDNA MAFs ≥5% at baseline status to be a significant predictor of OS (HR, 7.73, 95% CI, 2.61–22.91, P = .00002) on multivariate analysis. In the longitudinal analysis, an MAF peak above 1% in exoDNA was significantly associated with radiologic progression (P = .0003). CONCLUSIONS: In a prospective cohort of pancreatic cancer patients, we show how longitudinal monitoring using liquid biopsy samples through exoDNA and ctDNA provides both predictive and prognostic information relevant to therapeutic stratification.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2025) · doi:10.32614/r.manuals · Cited by 352,181
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
ggplot2: Elegant Graphics for Data Analysis
Wickham, H. (2009) · doi:10.1007/978-0-387-98141-3 · Cited by 14,447
Modeling Survival Data: Extending the Cox Model
Therneau, T. M., & Grambsch, P. M. (2000) · Statistics for Biology and Health · doi:10.1007/978-1-4757-3294-8 · Cited by 8,674
Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
Detection and localization of surgically resectable cancers with a multi-analyte blood test
Cohen, J. D., Li, L., Wang, Y., Thoburn, C., Afsari, B., Danilova, L., Douville, C., Javed, A. A., Wong, F., Mattox, A., et al. (2018) · Science · doi:10.1126/science.aar3247 · Cited by 2,783
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
The TRACERx consortium, Abbosh, C., The PEACE consortium, Birkbak, N. J., Wilson, G. A., Jamal-Hanjani, M., Constantin, T., Salari, R., Le Quesne, J., Moore, D. A., et al. (2017) · Nature · doi:10.1038/nature22364 · Cited by 1,874
Double-stranded DNA in exosomes: a novel biomarker in cancer detection
Thakur, B. K., Zhang, H., Becker, A., Matei, I., Huang, Y., Costa-Silva, B., Zheng, Y., Hoshino, A., Brazier, H., Xiang, J., et al. (2014) · Cell Research · doi:10.1038/cr.2014.44 · Cited by 1,596
Tie, J., Wang, Y., Tomasetti, C., Li, L., Springer, S., Kinde, I., Silliman, N., Tacey, M., Wong, H.-L., Christie, M., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf6219 · Cited by 1,492
Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer
Garcia-Murillas, I., Schiavon, G., Weigelt, B., Ng, C., Hrebien, S., Cutts, R. J., Cheang, M., Osin, P., Nerurkar, A., Kozarewa, I., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aab0021 · Cited by 1,150
Chaudhuri, A. A., Chabon, J. J., Lovejoy, A. F., Newman, A. M., Stehr, H., Azad, T. D., Khodadoust, M. S., Esfahani, M. S., Liu, C. L., Zhou, L., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0716 · Cited by 1,072
Kahlert, C., Melo, S. A., Protopopov, A., Tang, J., Seth, S., Koch, M., Zhang, J., Weitz, J., Chin, L., Futreal, A., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.c113.532267 · Cited by 1,026
8th Edition of the AJCC Cancer Staging Manual: Pancreas and Hepatobiliary Cancers
Chun, Y. S., Pawlik, T. M., & Vauthey, J.-N. (2018) · Annals of Surgical Oncology · doi:10.1245/s10434-017-6025-x · Cited by 812
Cohen, J. D., Javed, A. A., Thoburn, C., Wong, F., Tie, J., Gibbs, P., Schmidt, C. M., Yip-Schneider, M. T., Allen, P. J., Schattner, M., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1704961114 · Cited by 582
Self-citationAllenson, K., Castillo, J., San Lucas, F. A., Scelo, G., Kim, D. U., Bernard, V., Davis, G., Kumar, T., Katz, M., Overman, M. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx004 · Cited by 493
Self-citationSausen, M., Phallen, J., Adleff, V., Jones, S., Leary, R. J., Barrett, M. T., Anagnostou, V., Parpart-Li, S., Murphy, D., Kay Li, Q., et al. (2015) · Nature Communications · doi:10.1038/ncomms8686 · Cited by 484
Self-citationFurukawa, T., Kuboki, Y., Tanji, E., Yoshida, S., Hatori, T., Yamamoto, M., Shibata, N., Shimizu, K., Kamatani, N., & Shiratori, K. (2011) · Scientific Reports · doi:10.1038/srep00161 · Cited by 440
Detection of Cancer DNA in Plasma of Patients with Early-Stage Breast Cancer
Beaver, J. A., Jelovac, D., Balukrishna, S., Cochran, R. L., Croessmann, S., Zabransky, D. J., Wong, H. Y., Valda Toro, P., Cidado, J., Blair, B. G., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2933 · Cited by 398
Plasma Circulating Tumor DNA in Pancreatic Cancer Patients Is a Prognostic Marker
Pietrasz, D., Pécuchet, N., Garlan, F., Didelot, A., Dubreuil, O., Doat, S., Imbert-Bismut, F., Karoui, M., Vaillant, J.-C., Taly, V., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0806 · Cited by 268
Castillo, J., Bernard, V., San Lucas, F. A., Allenson, K., Capello, M., Kim, D. U., Gascoyne, P., Mulu, F. C., Stephens, B. M., Huang, J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx542 · Cited by 267
Self-citationSan Lucas, F. A., Allenson, K., Bernard, V., Castillo, J., Kim, D. U., Ellis, K., Ehli, E. A., Davies, G. E., Petersen, J. L., Li, D., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdv604 · Cited by 204
Self-citationEarl, J., Garcia-Nieto, S., Martinez-Avila, J. C., Montans, J., Sanjuanbenito, A., Rodríguez-Garrote, M., Lisa, E., Mendía, E., Lobo, E., Malats, N., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1779-7 · Cited by 179
Hadano, N., Murakami, Y., Uemura, K., Hashimoto, Y., Kondo, N., Nakagawa, N., Sueda, T., & Hiyama, E. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.175 · Cited by 171
Comparison of 2 Commercially Available Next-Generation Sequencing Platforms in Oncology
Kuderer, N. M., Burton, K. A., Blau, S., Rose, A. L., Parker, S., Lyman, G. H., & Blau, C. A. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.4983 · Cited by 170
Möhrmann, L., Huang, H. J., Hong, D. S., Tsimberidou, A. M., Fu, S., Piha-Paul, S. A., Subbiah, V., Karp, D. D., Naing, A., Krug, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2007 · Cited by 166
Tjensvoll, K., Lapin, M., Buhl, T., Oltedal, S., Berry, K. S.-O., Gilje, B., Søreide, J. A., Javle, M. M., Nordgård, O., & Smaaland, R. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.11.012 · Cited by 163
Self-citationUse of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients
Schwaederle, M. C., Husain, H., Fanta, P. T., Piccioni, D. E., Kesari, S., Schwab, R. B., Patel, S. P., Harismendy, O., Ikeda, M., Parker, B. A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0318 · Cited by 155
Chae, Y. K., Davis, A. A., Jain, S., Santa-Maria, C. A., Flaum, L., Beaubier, N. T., Platanias, L. C., Gradishar, W. J., Giles, F. J., & Cristofanilli, M. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0061 · Cited by 144
Maire, F., Micard, S., Hammel, P. R., Voitot, H., Lévy, P., Cugnenc, P., Ruszniewski, P. B., & Laurent‐Puig, P. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600475 · Cited by 142
Cloyd, J. M., Wang, H., Egger, M. E., Tzeng, C.-W. D., Prakash, L. R., Maitra, A., Varadhachary, G. R., Shroff, R., Javle, M., Fogelman, D., et al. (2017) · JAMA Surgery · doi:10.1001/jamasurg.2017.2227 · Cited by 112
Self-citationLee, J. H., Kim, Y., Choi, J.-W., & Kim, Y. (2016) · SpringerPlus · doi:10.1186/s40064-016-2847-4 · Cited by 111
L�ttges, J., Diederichs, A., Menke, M. A. O. H., Vogel, I., Kremer, B., & Kl�ppel, G. (2000) · Cancer · doi:10.1002/1097-0142(20000601)88:11<2495::aid-cncr10>3.0.co;2-b · Cited by 94
KRASmutations in blood circulating cell-free DNA: a pancreatic cancer case-control
Calvez‐Kelm, F. L., Foll, M., Wozniak, M. B., Delhomme, T. M., Durand, G., Chopard, P., Pertesi, M., Fabiánová, E., Adamčáková, Z. K., Holcátová, I., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12386 · Cited by 88
Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer
Villaflor, V., Won, B., Nagy, R., Banks, K., Lanman, R. B., Talasaz, A., & Salgia, R. (2016) · Oncotarget · doi:10.18632/oncotarget.11801 · Cited by 75
Hahn, A. W., Gill, D. M., Maughan, B. L., Agarwal, A. M., Arjyal, L., Gupta, S. V., Streeter, J., Bailey, E. B., Pal, S. K., & Agarwal, N. (2017) · Oncotarget · doi:10.18632/oncotarget.16833 · Cited by 62
Takai, E., Totoki, Y., Nakamura, H. K., Kato, M., Shibata, T., & Yachida, S. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-42044-8_3 · Cited by 38
Toor, O. M., Ahmed, Z., Bahaj, W., Boda, U., Cummings, L. S., McNally, M. E., Kennedy, K. F., Pluard, T., Hussain, A., Subramanian, J., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1015 · Cited by 23
Cited by
The biology , function , and biomedical applications of exosomes
Kalluri, R., & LeBleu, V. S. (2020) · Science · doi:10.1126/science.aau6977 · Cited by 10,770
Exosome-Mediated Metastasis: Communication from a Distance
Wortzel, I., Dror, S., Kenific, C. M., & Lyden, D. (2019) · Developmental Cell · doi:10.1016/j.devcel.2019.04.011 · Cited by 1,285
Tumour evolution in hepatocellular carcinoma
Craig, A. J., von Felden, J., Garcia-Lezana, T., Sarcognato, S., & Villanueva, A. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0229-4 · Cited by 823
Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer
Buscail, L., Bournet, B., & Cordelier, P. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0245-4 · Cited by 721
Application of exosomes as liquid biopsy in clinical diagnosis
Zhou, B., Xu, K., Zheng, X., Chen, T., Wang, J., Song, Y., Shao, Y., & Zheng, S. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00258-9 · Cited by 685
Metadata
- Authors
- Bernard, V., Kim, D. U., San Lucas, F. A., Castillo, J., Allenson, K., Mulu, F. C., Stephens, B. M., Huang, J., Semaan, A., Guerrero, P. A., Kamyabi, N., Zhao, J., Hurd, M. W., Koay, E. J., Taniguchi, C. M., Herman, J. M., Javle, M., Wolff, R., Katz, M., Varadhachary, G., Maitra, A., & Alvarez, H. A.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2019-01
- Volume
- 156
- Issue
- 1
- Pages
- 108-118.e4
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2890106882
- Cited by
- 363
- References
- 39
- FWCI
- 11.24
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.